At a China Bio meeting, CAE Academician SHEN Beifen described the situation of antibody drugs in China as follows: 22 antibody drugs approved in China, 10 out of them „made in China“. Over 400 applications pending at China FDA. Still more than 100 enterprises develop monoclonal antibody drugs. In 2014, China’s antibody drug market reached over 6 billion yuan and is expected, by 2025, to reach more than 30 billion yuan.

China Bio news release, July 18, 2016